linjc16/ctgov huggingface dataset:
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Study Overview
=================
Brief Summary
-----------------
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. Evaluate prospectively the sensitivity and specificity of dual energy computed tomography (CT) in detecting primary gastrointestinal (GI) carcinoid. OUTLINE: Patients undergo one dual energy CT scan during scheduled CT scan.

Official Title
-----------------
Evaluation of Dual Energy CT for the Detection of Gastrointestinal Carcinoids

Conditions
-----------------
Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor

Intervention / Treatment
-----------------
* Procedure: Dual-Energy Computed Tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with: clinical features of carcinoid syndrome (or) increased serum and urinary markers suggestive of carcinoid (or) endoscopic biopsy proven carcinoid (or) metastases which are biopsy proven as carcinoid. Patient is scheduled to have a clinically indicated staging CT exam. Patients who have signed their informed consent form to undergo the study. Exclusion Criteria: Patients who have already had their primary GI carcinoid resected. Contraindication to intravenous contrast agents (e.g. allergy, renal failure, dialysis, pregnancy etc.). Pregnant patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diagnostic (dual energy CT scan)<br>Patients undergo one dual energy CT scan during scheduled CT scan. | Procedure: Dual-Energy Computed Tomography<br>* Undergo dual energy CT scan<br>* Other names: DECT;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors |  | through study completion, an average of 1 year |
Viscosupplementation in the Hip Following Hip Arthroscopy

Study Overview
=================
Brief Summary
-----------------
Hip arthroscopy is a rapidly evolving procedure that has seen an exponential increase in the number of cases performed yearly. With hip arthroscopy still in its infancy in relation to knee and shoulder arthroscopy, there are still many questions yet to be answered. Axioms that were once thought to be true regarding indications and treatment for hip arthroscopy are continually being revised. As with the knee and shoulder before it, the hip is now graduating into treatment avenues that were otherwise thought to only be possible through an open surgical procedure. Viscosupplementation in patients post arthroscopy with known articular cartilage injury has been shown to be efficacious. The pathophysiology of hyaline degradation during the arthritic process within the knee has been studied, and with this understanding has grown the widespread usage of viscosupplementation. While questions still exist regarding the effectiveness of viscosupplementation in non-weightbearing joints, it appears the benefits seen in the weight bearing joints, such as the knee, are apparent

Official Title
-----------------
Viscosupplementation in the Hip Following Hip Arthroscopy

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Monovisc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preoperative inclusion criteria will be made via x-ray and MRI evaluation. These criteria shall include: 2 mm or greater joint space preservation of the hip on radiographs, absence of acetabular subcortical bone cysts, Tonnis Score less than 2 on radiographs, and patient age greater than 18.4 Intra-operative evaluation of the cartilage will be performed by the surgeon on both the acetabular and femoral head sides. Patients shall be included if the osteochondral defect meets Outerbridge Classification criteria of stage II or greater. Furthermore the lesion shall be greater than 1cm in size (and thus not amenable to other procedures such as microfracture). Subjects must be willing to sign the IRB-approved informed consent and be older than 18 years old. Exclusion Criteria: All patients 55 years of age and older. All patients with previous hip surgery on a concomitant side. Patients who present a history of radiculopathy or regional pain syndrome. Patients with a worker's compensation claim or pending litigation claim. Patients with Outerbridge Grade IV changes on either acetabular or femoral articular cartilage.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Monovisc|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Using Visual Analog Scale | Using Visual Analog Scale | Up to 12 months |
The Energy Balance Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study if to determine the specific contributions of energy intake and energy expenditure to changes in body weight and fat.

Detailed Description
-----------------
Changes in body weight and fat will be positively associated with increases in total energy intake. Changes in body weight and fat will be positively associated with decreases in total energy expenditure.

Conditions
-----------------
Total Energy Expenditure,Total Energy Intake

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI: 20-35 *Note : For participants that come to Orientation, we are allowing participants with a variance of 0.1 either way in the BMI range: 19.9 - 35.1 21-35 years of age Men and women Email address Access to a phone Exclusion Criteria: Currently on medications to lose weight >90th percentile on the Brief Symptom Inventory (BSI) Planning to move from the Greater Columbia area in the next 15 months Other medical, psychiatric or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention protocol. Changed birth control status in past 3 months Currently taking birth control but plan to stop taking it within the next 12 months or are planning to start taking birth control in the next 12 months Planning to have weight loss surgery Started or stopped smoking in the past 6 months Blood pressure ≥ 150/90 Blood glucose ≥ 145 mg/dL @ orientation Blood glucose ≥ 126 mg/dL @ B3 Total cholesterol ≥ 240 mg/dl with LDL-C ≥ 190 mg/dl or Triglyceride levels ≥ 300 mg/dL Currently diagnosed with or taking medications for a major chronic health condition Presence of an eating disorder Currently participating in another study

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 21-35 years of age<br>200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| variation in total energy expenditure and variation in total energy intake contribute to changes in body weight and fat among young adults |  | two years |
Death Rattle - A Double Blind, Randomly Controlled, Crossover Trial

Study Overview
=================
Brief Summary
-----------------
Dying patients are often unable to clear secretions from their large airways, resulting in noisy breathing usually described as death rattle. While there is no evidence that patients find this condition disturbing, the noises may be disturbing to the patient's visitors and caregivers who may fear that the patient is choking to death. In Israel none of the pharmaceutical drugs listed in the literature exist. Thus, Atropine drops which have been noted in the literature as being used, though according to our knowledge no evidence of clinical trials using sublingual Atropine were conducted. The study is designed as a randomly controlled, double blind crossover trial. The patient will serve as control for himself, as crossover between placebo and drug (randomly chosen) will take place. The administrator of the drug will be blinded to the medication, each time randomly beginning with a different drug (placebo or Atropine). We will evaluate Atropine Sulphate 1% ophthalmic drops effect on 33 patients using a noise score scale of 0-3. Noise scores will be taken at the start; 30 min after drug/placebo administration and every hour thereafter. After 4-hours crossover will take place and evaluation will follow the same protocol.

Official Title
-----------------
Death Rattle - A Double Blind, Randomly Controlled, Crossover Trial

Conditions
-----------------
Noise, Death

Intervention / Treatment
-----------------
* Drug: Atropine Sulphate 1% ophthalmic drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: : Patients belonging to Home Palliative Care Unit of Clalit Health Services - Southern District, and the Oncology Department of Soroka University Medical Center and suffering from death rattle will be recruited for the study. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Noise Level | 30 min after drug administration; and hourly after the initial administration. if needed a repeat dose will be given and the noise score will be evaluated at 30 min; and hourly thereafter. The repeat dose will be left to the nurses' discretion if they thought the rattle to be unacceptable. | 8 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Death Rattle, Noise level, Primary Care
Healthy Infant Development Project - Sucrose Component

Study Overview
=================
Brief Summary
-----------------
Iron deficiency affects the opioid and dopamine systems in rodent models, with a higher pain threshold. The opioid system is involved in sucrose's ability to reduce pain and distress during neonatal procedures. Thus, prenatal iron deficiency might affect response to pain and sucrose analgesia. In order to compare response to pain and sucrose during heel stick in neonates with and without iron deficiency, healthy full-term Chinese infants were randomized to receive sucrose or water by syringe beforehand, in conjunction with heel stick for metabolic screening.

Official Title
-----------------
Timing, Duration and Severity of Infant Iron Deficiency: Developmental Impacts - Sucrose Component

Conditions
-----------------
Iron Deficiency

Intervention / Treatment
-----------------
* Other: Water
* Other: Sucrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Full term healthy neonates participating in the Healthy Infant Development RCT (NCT00613717) in the folic acid/early postnatal placebo group and pre- and early postnatal iron-supplemented infants. Exclusion Criteria: birth weight < 2500 g gestational age ≤ 37 wk major perinatal complications major congenital anomaly multiple birth

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Water<br>Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick. | Other: Water<br>* 2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick<br>|
| Active Comparator: Sucrose<br>Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick. | Other: Sucrose<br>* 2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infant behavior (emotion regulation) | Infant behavior observed included activity level, negative emotionality, alertness and soothability. | up to 5 days old |
Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders

Study Overview
=================
Brief Summary
-----------------
To assess the effect of a probiotic product, when co-administered with antibiotics, on gastrointestinal symptoms following antibiotic treatment in children.

Conditions
-----------------
Antibiotic-associated Diarrhea

Intervention / Treatment
-----------------
* Dietary Supplement: Probiotics
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children at the age of 1-11 years that have been prescribed antibiotic treatment. Problems with loose stools during earlier antibiotic treatments. Children whose parents or legal caregivers have signed the informed consent to participate in the study. Exclusion Criteria: Chronic intestinal disease, immunodeficiency or immunosuppressive treatment. Chronic or acute diarrheal disease. Use of laxatives the week before inclusion in the study. Antibiotic treatment for the last four weeks before inclusion in the study. Intake of probiotic products for the last two weeks before inclusion in the study. Known hypersensitivity to any of the ingredients in the probiotic product or the placebo (potato starch ± bacterial culture that may contain traces of soy). Patient requiring hospitalisation.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Probiotics<br> | Dietary Supplement: Probiotics<br> <br> |
| Placebo Comparator: Placebo<br> | Dietary Supplement: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of loose/watery stools |  | 19-26 days |
Relationship Between a Combined Index of Diastolic and Systolic Performance and Intraoperative Hemodynamic Changes During Off-pump Coronary Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
As considering the close relationship between systolic dysfunction and diastolic dysfunction, the EAS index e'/(a' x s') including systolic and diastolic function could be expected to predict hemodynamic changes during off-pump coronary artery bypass surgery(OPCAB). Exposure of the grafting site during OPCAB needs displacement of the heart, resulting in hemodynamic instability. Therefore the investigators are going to evaluate EAS index with preoperative Transthoracic echocardiography(TTE) and want to know the relationship between preoperative EAS index and intraoperative hemodynamic changes in patients undergoing OPCAB, in a prospective observational study.

Conditions
-----------------
Coronary Artery Obstructive Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 20 Patients undergoing multivessel off-pump coronary artery bypass surgery Exclusion Criteria: Age < 20 Patients with valvular heart disease Congestive heart failure, NYHA class ≥III Emergency surgery Patients with arrhythmia ST segment elevation myocardial infarction

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sequential changes of SvO2 | Mixed venous oxygen saturation(SvO2) reflects the balance of oxygen supply and demand immediately. Cardiac index(CI) also is a useful marker of how well the heart is functioning. Both variables can show the hemodynamic instability. With the comparison of EAS index and variables including SvO2 and CI, Investigator may draw the predictable value of the EAS index for predicting hemodynamic instability during OPCAB. | during OPCAB surgery | 
| sequential changes of CI |  | during OPCAB surgery |
Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Carriage Rates in Resident Physicians

Study Overview
=================
Brief Summary
-----------------
One hundred new residents will be recruited prior to the start of residency and followed prospectively for a year. Monthly nasal swabs will be performed to identify colonization with methicillin resistant staphylococcus aureus (MRSA).The proportion of study subjects colonized with MRSA at the end of 1 year will be calculated.

Detailed Description
-----------------
This is a prospective observational study looking at the incidence of MRSA colonization. New residents will be monitored every month with nasal swabs.We would like to elucidate factors responsible for MRSA colonization in healthcare workers.We would like to see if health care workers who are colonized spontaneously cleared MRSA and if there was any factors involved. Nasal swabs will be plated on the spot by trained individuals and the plates then incubated for 48 hours. Plates will be read by microbiologist after incubation.

Official Title
-----------------
The Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Nasal Carriage Among Resident Physicians

Conditions
-----------------
MRSA Colonization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study subjects will be newly appointed residents at the OU medical center Exclusion Criteria: Previous MRSA infection Current use of mupirocin

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MRSA surveillance<br>Newly recruited resident physicians will be monitored for a year with nasal swabs monthly. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To detect an increase in MRSA nasal carriage rate among newly appointed residents after 1 year of regular patient contact. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRSA, Contact isolation, Incidence
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

Study Overview
=================
Brief Summary
-----------------
This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.

Official Title
-----------------
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

Conditions
-----------------
Pancreatic Neoplasms

Intervention / Treatment
-----------------
* Other: No intervention will be considered in this study.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18, both male and female; Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging; Clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments); You can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for tumors; The subject voluntarily joined the study and signed an informed consent form voluntarily. Exclusion Criteria: 1. Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single arm<br>Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent. | Other: No intervention will be considered in this study.<br>* No intervention will be considered in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | overall survival | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DFS | disease free survival | 5 years | 
| PFS | progress free survival | 5 years |